Le Lézard
Classified in: Health
Subject: FDA

Pharmaceutics International Receives EIR from FDA


HUNT VALLEY, Md., March 14, 2019 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a Contract Development and Manufacturing Organization (CDMO) today announced that the U.S. Food and Drug Administration (FDA) has issued their Establishment Inspection Reports (EIRs) for both FEI registration numbers (1000513101/3006503102), covering Pii's facilities in Hunt Valley and Cockeysville, MD.  The EIRs are related to General and Pre-Approval Inspections (PAIs) that occurred between October 23rd and November 9th, 2018, of non-sterile and sterile drug production facilities.  Both EIRs indicate that Pii's facilities are at "voluntary action indicated" or VAI status, which means the Agency found Pii to be in an acceptable state of compliance.  Subsequent to the FDA's inspection, and facility status recommendation, Pii has gained the FDA's approval of 4 sterile and non-sterile products.

Pharmaceutics International, Inc, (PRNewsFoto/Pharmaceutics International, Inc)

"The successful completion of the FDA facility inspection is a very positive development for Pii, as we continue on our journey to meet and exceed U.S. and international regulatory requirements.  Pii will continue to address observations noted during the inspection, and strive for the highest standard of product quality, compliance and customer service," said Dr. Kurt Nielsen, Pii's President and CEO. 

About Pharmaceutics International, Inc.

Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland USA, Pii's services include pre-formulation development, and clinical and commercial cGMP manufacturing of parenterals, liquid solutions and oral solids, including soft gels, tablets and capsules. In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances.  For more information, please visit www.pharm-int.com.

Contact: 
Kurt R. Nielsen, Ph.D., President and CEO 
Pharmaceutics International, Inc. 
10819 Gilroy Road 
Hunt Valley, MD 21031 
Phone: (410) 584-0001 
Email:  knielsen@pharm-int.com

SOURCE Pharmaceutics International, Inc.


These press releases may also interest you

3 jui 2020
Daiya Foods Inc. is recalling Daiya brand Classic Vanilla Creme Non-Dairy Frozen Dessert from the marketplace because it contains milk which is not declared on the label. People with an allergy to milk should not consume the recalled product...

3 jui 2020
The global patient temperature management market is expected to grow by USD 1.09 billion as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of...

3 jui 2020
MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Charleston, South Carolina. The guide identifies 5 memory care communities based on location,...

3 jui 2020
Bird Construction Inc. is pleased to announce the sale of Bird Capital Limited's 20 per cent interest in the P3 concessions responsible for 18 schools and nine childcare facilities in Saskatchewan to its project partner, Concert Infrastructure....

3 jui 2020
Minnesota-based parkour gym Fight or Flight Academy, is hosting an online parkour competition with a $10,000 prize, the largest prize in parkour history, to help promote the upcoming launch of their online parkour academy.  ...

3 jui 2020
Winpak Ltd. (the "Corporation") is pleased to announce that the nominees listed in the management proxy circular dated February 21, 2020, were elected as directors of the Corporation at the Corporation's Annual Meeting of Shareholders held virtually...



News published on 14 march 2019 at 10:20 and distributed by: